Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590050 | 1.00 | CHUK (0.45) | CHUKNLRP3NR1I2ALBPDE4D | |
| Hydrochloric Acid SCHEMBL8971259 | 0.98 | CHUK (0.44) | CHUKNLRP3NR1I2ALBPDE4D | |
| SCHEMBL7626873 | 0.94 | CHUK (0.47) | CHUKNLRP3LMNAHTTPAK1 | |
| SCHEMBL7621597 | 0.94 | CHUK (0.50) | CHUKLMNAHTTPAK1PKM | |
| SCHEMBL797050 | 0.92 | CHUK (0.52) | CHUKLMNAHTTPAK1JAK1 | |
| Quinoline SCHEMBL28784541 | 0.85 | PIK3CD (0.44) | CHUKNLRP3SYKADORA3ADORA2A | |
| SCHEMBL19510140 | 0.84 | CHUK (0.35) | CHUKNLRP3NR1I2ALBPDE4D | |
| SCHEMBL16146711 | 0.81 | LRRK2 (0.39) | PDE4DLMNAHTTPAK1PKM | |
| SCHEMBL7111201 | 0.81 | ADORA3 (0.41) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL16146849 | 0.81 | LMNA (0.38) | CHUKLMNAHTTPAK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-6444656-B1 | (5R)-(2-AMINO-6-HYDROXY-PURIN-9-YLMETHYL)-(4R)-AZIDO-TETRAHYDR O-FURAN-(2S)- PHOSPHONATE; PARTICULARLY AGAINST HIV AND/OR HBV INFECTIONS | BIOCHEM PHARMA, INC. (CA) | 2002-09-03 | — | — | US | claimed |
| EP-1032573-A1 | PROCESS FOR PREPARING A CHIRAL NUCLEOSIDE ANALOGUE | GLAXO GROUP LIMITED (GB) | 2000-09-06 | — | — | EP | claimed |
| WO-1999024431-A1 | PROCESS FOR PREPARING A CHIRAL NUCLEOSIDE ANALOGUE | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| WO-1998030563-A1 | 2-HYDROXYMETHYLCYCLOPROPYLI- DENEMETHYLPURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-07-16 | — | — | WO | claimed |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4499106-A2 | NUCLEOSIDE LINE-1 INHIBITORS | Transposon Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-3512863-B1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | ATEA PHARMACEUTICALS INC (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021209563-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-10-21 | — | — | WO | disclosed |
| EP-3865136-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-0620734-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-10-26 | — | — | EP | disclosed |
| WO-1994001443-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| CN-1077199-A | THERAPEUTIC NUCLEOSIDES | WELLCOME FOUND (GB) | 1993-10-13 | — | — | CN | disclosed |
| WO-1993013778-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CHUK 426/4885NLRP3 1254/4885NR1I2 2596/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | CHUK 819/4885NLRP3 1303/4885NR1I2 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.